U.S., Feb. 14 -- ClinicalTrials.gov registry received information related to the study (NCT06825702) titled 'Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients with Macular Edema' on Feb. 04.
Brief Summary: This is a multi-center, open label study to assess the safety, tolerability, and efficacy of KIO-104 administered by IVT injection to the study eye of eligible participants with macular edema.
Study Start Date: April, 2025
Study Type: INTERVENTIONAL
Condition:
Macular Edema
Intervention:
DRUG: KIO-104
KIO-104 is an ophthalmic formulation for IVT injection of the active pharmaceutical ingredient (API) KIO-100, a novel, non-steroidal, small molecule inhibitor of dihydroorotate dehydrogenase (DHODH).
Recruitment ...